425 results
Search Results
2. Systematic review: health-related quality of life in children and adults with eosinophilic oesophagitis-instruments for measurement and determinant factors.
3. Editorial: protecting hypoxia‐inducible factor 1a and gut integrity with GB004—a promising therapeutic approach for ulcerative colitis? Authors' reply.
4. Editorial: protecting hypoxia‐inducible factor‐1α and gut integrity with GB004—a promising therapeutic approach for ulcerative colitis?
5. Editorial: Novel insights into the prognostic relevance of high‐dose PPI treatment in patients with cirrhosis.
6. Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B.
7. Letter: loss of response to anti‐TNFα agents in patients with inflammatory bowel disease depends on treatment duration.
8. Editorial: bezafibrate in the treatment of patients with primary biliary cholangitis—are we there yet? Authors' reply.
9. Editorial: acute non‐cirrhotic and non‐malignant portal vein thrombosis—who should be candidates for interventional treatment?
10. Systematic review: Heliocobacter pylori infection and impaired drug absorption.
11. The association between hepatocellular carcinoma and direct‐acting anti‐viral treatment in patients with decompensated cirrhosis.
12. Editorial: P‐CABs for treatment of reflux oesophagitis—is this the future?
13. Editorial: recognising the efficacy of licensed drug therapies for irritable bowel syndrome on bloating—a step in the right direction for targeted treatment? Authors' reply.
14. Editorial: total anti‐drug antibodies detected using drug‐tolerant assays during induction with anti‐TNF therapy are associated with treatment failure—out of sight but not out of mind. Authors' reply.
15. Editorial: total anti‐drug antibodies detected using drug‐tolerant assays during induction with anti‐TNF therapy are associated with treatment failure—out of sight but not out of mind.
16. Editorial: standardising inclusion and outcome criteria for pouchitis—a fragile consensus perhaps but a first step in the right direction.
17. Editorial: standardising inclusion and outcome criteria for pouchitis—a fragile consensus perhaps but a first step in the right direction. Authors' reply.
18. Editorial: Time to consider early treatment for chronic hepatitis B in both children and adults—authors' reply.
19. Editorial: Time to consider early treatment for chronic hepatitis B in both children and adults.
20. Letter: hepatocellular carcinoma negatively affects sustained virological response of direct‐acting anti‐viral treatment in decompensated cirrhosis.
21. Editorial: a need for glucose monitoring on prokinetic treatment with a ghrelin agonist in diabetic gastroparesis?
22. Letter: addition of methotrexate neither restores clinical response nor improves the pharmacokinetic profile of vedolizumab-treated patients.
23. Letter: non‐invasive transabdominal stimulation device for the treatment of chronic constipation—proof‐of‐principle study in adults. Authors' reply.
24. Editorial: response to tofacitinib is associated with high rates of long‐term treatment persistence.
25. Editorial: symptom improvement does not equal satisfaction with treatment for constipation—authors' reply.
26. Editorial: HBV—the promise of a new era in therapeutics.
27. Editorial: interventions in infantile colic – can efficacy be attributed to treatment or to time? Authors' reply.
28. Editorial: interventions in infantile colic – can efficacy be attributed to treatment or to time?
29. Letter: a 5‐year long‐term follow‐up study after DAA treatment confirms a reduced HCC risk in a central European cohort of HCV patients with liver cirrhosis.
30. Editorial: targeting aberrant hepatic inflammation for treatment of non‐alcoholic steatohepatitis.
31. Editorial: targeting aberrant hepatic inflammation for treatment of non‐alcoholic steatohepatitis—authors' reply.
32. Editorial: early and persistent biological treatment and its impact on long term surgical outcomes in inflammatory bowel disease.
33. Editorial: bezafibrate in the treatment of patients with primary biliary cholangitis—are we there yet?
34. Systematic review with meta-analysis: the management of chronic refractory pouchitis with an evidence-based treatment algorithm.
35. Review article: the potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection.
36. Editorial: does anti‐TNF 'treatment persistence' always equate to 'effective treatment'? Only objective disease assessments can answer the question. Authors' reply.
37. Editorial: does anti‐TNF "treatment persistence" always equate to "effective treatment"? Only objective disease assessments can answer the question.
38. Editorial: recognising the efficacy of licensed drug therapies for IBS on bloating—a step in the right direction for targeted treatment?
39. Editorial: on the road towards treatment of gastroparesis—accelerating, but do we get closer? Authors' reply.
40. Editorial: on the road towards treatment of gastroparesis—accelerating but do we get closer?
41. Editorial: anti-tumour necrosis factor α antibodies - can efficacy be regained?
42. Editorial: anti‐TNF agents against vedolizumab as a second‐line treatment? Not surprising tie game—authors' reply.
43. Editorial: anti‐TNF agents against vedolizumab as a second‐line treatment? Not surprising tie game.
44. Systematic review: the treatment of muscle cramps in patients with cirrhosis.
45. Letter: clinical response to pioglitazone in nonalcoholic steatohepatitis [ NASH] treatment-use of pharmacokinetic surrogate.
46. Editorial: biomarkers in HBV and prediction of treatment response.
47. Editorial: ONO-2952 in irritable bowel syndrome with diarrhoea.
48. Letter: sequential or combined systemic treatment for unresectable hepatocellular carcinoma—authors' reply.
49. Letter: sequential or combinated systemic treatment for unresectable hepatocellular carcinoma.
50. Editorial: international consensus in clinical trial end-points in ulcerative colitis - clarity or just a step in clearing the fog?
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.